紫杉醇胶束对比Cremophor EL-紫杉醇治疗铂敏感复发卵巢癌的随机III期试验
这项多中心、开放标签、随机III期试验纳入789例铂敏感复发卵巢/输卵管/腹膜癌患者,比较紫杉醇胶束(250 mg/m²,1小时输注)联合卡铂与Cremophor EL-紫杉醇(175 mg/m²,3小时输注)联合卡铂的疗效与安全性。主要终点PFS在符合方案人群中显示紫杉醇胶束非劣效(HR 0.86,95%CI 0.72-1.03),OS亦非劣效(HR 0.95,95%CI 0.78-1.16)。
要点
- PFS在PP人群HR 0.86(95%CI 0.72-1.03),非劣效界值1.2,支持紫杉醇胶束非劣效。
- OS在PP人群HR 0.95(95%CI 0.78-1.16),非劣效界值1.185,支持紫杉醇胶束非劣效。
- 最常见的≥3级不良事件为中性粒细胞减少:紫杉醇胶束组245例(79%)vs Cr-EL紫杉醇组213例(66%)。
核心结论
- 在研究的铂敏感复发卵巢癌人群中,紫杉醇胶束联合卡铂在PFS和OS方面非劣效于Cremophor EL-紫杉醇联合卡铂。
- 紫杉醇胶束提供了更高紫杉醇剂量、更短输注时间且无需强制预处理的治疗选择。
研究设计与样本
- 多中心、开放标签、随机III期试验,2009至2013年随机789例患者(实验组N=397,对照组N=392)。
- 成人复发患者接受6个3周周期:紫杉醇胶束250 mg/m² 1小时输注或Cr-EL紫杉醇175 mg/m² 3小时输注,两组均联合卡铂AUC 5-6。
- 主要终点为基于CT扫描的PFS非劣效性,OS为次要终点。
主要发现
- PFS在PP人群HR 0.86(95%CI 0.72-1.03),非劣效界值1.2,支持紫杉醇胶束非劣效。
- OS在PP人群HR 0.95(95%CI 0.78-1.16),非劣效界值1.185,支持紫杉醇胶束非劣效。
- 最常见的≥3级不良事件为中性粒细胞减少:紫杉醇胶束组245例(79%)vs Cr-EL紫杉醇组213例(66%)。
- 周围感觉神经病变(任意级别)两组相似:紫杉醇胶束组16% vs Cr-EL紫杉醇组20%。
关键数值与推荐
- PFS非劣效界值为1.2,PP人群HR 0.86(95%CI 0.72-1.03)。
- OS非劣效界值为1.185,PP人群HR 0.95(95%CI 0.78-1.16)。
- 紫杉醇胶束剂量250 mg/m² 1小时输注,Cr-EL紫杉醇剂量175 mg/m² 3小时输注,卡铂AUC 5-6。
临床怎么用
- 对于铂敏感复发卵巢、输卵管或腹膜癌患者,紫杉醇胶束联合卡铂可作为与Cr-EL紫杉醇联合卡铂疗效非劣效的选项。
- 紫杉醇胶束方案可使用更高紫杉醇剂量(250 mg/m²)、更短输注时间(1小时)且无需强制预处理。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Paclitaxel micellar was developed to avoid Cremophor-EL (Cr-EL) associated dose limiting toxicity and to allow a shorter infusion time. The efficacy and safety of paclitaxel micellar (+carboplatin) was compared to Cr-EL paclitaxel (+carboplatin) in recurrent platinum-sensitive ovarian, fallopian tube or peritoneal carcinoma. METHODS: This was a multicentre, open-label, randomized phase III trial. Adult patients with recurrent disease was assigned to six 3-week cycles of paclitaxel micellar (250 mg/m2) administered as 1-h infusion or Cr-EL paclitaxel (175 mg/m2) as 3-h infusion. Both arms received carboplatin (AUC 5-6). Primary objective was non-inferiority for progression free survival (PFS) using computed tomography scans. Overall survival (OS) was included as secondary endpoint. RESULTS: Between 2009 and 2013, 789 patients were randomized to receive experimental (N = 397) or control (N = 392) treatment. PFS for paclitaxel micellar was non-inferior to Cr-EL paclitaxel with a hazard ratio of 0.86 (95% CI: 0.72;1.03) in the per protocol population (PP), favouring paclitaxel micellar (non-inferiority margin was 1.2). Non-inferiority of OS was shown in the PP population with a hazard ratio of 0.95 (95% CI: 0.78; 1.16), favouring paclitaxel micellar (non-inferiority margin was 1.185). The most common adverse event was neutropenia (grade ≥ 3); 245 patients (79%) for paclitaxel micellar vs 213 patients (66%) for Cr-EL paclitaxel. The frequency of peripheral sensory neuropathy (any grade) was similar between the arms; 16% for paclitaxel micellar and 20% for Cr-EL paclitaxel. CONCLUSION: Paclitaxel micellar (+ carboplatin) is non-inferior to Cr-EL paclitaxel (+ carboplatin) in terms of PFS and OS in the studied population. It provides a treatment option of a higher paclitaxel dose with a shorter infusion time without mandatory premedication. TRIAL REGISTRATION NUMBER: 2008-002668-32 (EudraCT), NCT00989131 (ClinicalTrials.gov).
引用
- Vergote I, Bergfeldt K, Franquet A, et al. A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel. Gynecol Oncol. 2019. PMID: 31826802. doi:10.1016/j.ygyno.2019.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。